INAB

IN8bio Inc

Apr 09 • 04:00PM ET

1.43

-0.02 -1.38 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA GILD ADAP CLLS FATE BLUE EDIT IBRX TCRT

Index	-	P/E	-	EPS (ttm)	-4.59	Insider Own	13.12%	Shs Outstand	9.77M	Perf Week	2.14%
Market Cap	14.08M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	0.00%	Shs Float	8.56M	Perf Month	-20.99%
Enterprise Value	-10.23M	PEG	-	EPS next Q	-0.54	Inst Own	31.30%	Short Float	1.86%	Perf Quarter	-42.80%
Income	-19.44M	P/S	-	EPS this Y	52.93%	Inst Trans	30.56%	Short Ratio	2.37	Perf Half Y	-41.87%
Sales	0.00M	P/B	0.51	EPS next Y	27.87%	ROA	-71.64%	Short Interest	0.16M	Perf YTD	-38.89%
Book/sh	2.82	P/C	0.52	EPS next 5Y	39.02%	ROE	-92.49%	52W High	5.82 -75.42%	Perf Year	-68.78%
Cash/sh	2.75	P/FCF	-	EPS past 3/5Y	52.25% 22.63%	ROIC	-66.76%	52W Low	1.17 22.22%	Perf 3Y	-95.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.59% 10.51%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	75.49%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.82	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.08	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.82	EPS Q/Q	80.15%	SMA20	-11.84%	Beta	0.05	Target Price	6.25
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-17.40%	Rel Volume	0.78	Prev Close	1.45
Employees	17	LT Debt/Eq	0.06	Earnings	Mar 12 AMC	SMA200	-28.47%	Avg Volume	67.29K	Price	1.43
IPO	Jul 30, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	29.74% -	Trades		Volume	52,726	Change	-1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Laidlaw	Buy	$7.50
Aug-30-22	Initiated	H.C. Wainwright	Buy	$14

Apr-03-26 04:00PM	IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 04:01PM	IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 (GlobeNewswire)
Feb-24-26 08:00AM	IN8bio to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-09-26 08:00AM	IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer (GlobeNewswire)
Feb-03-26 08:00AM	IN8bio to Present at Upcoming Investor and Scientific Conferences in February (GlobeNewswire)
08:00AM	Loading…
Jan-12-26 08:00AM	IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma (GlobeNewswire) -7.23%
Dec-19-25 08:00AM	IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager (GlobeNewswire) -12.32%
Nov-06-25 04:00PM	IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.63%
Oct-29-25 08:00AM	IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site (GlobeNewswire)
Oct-27-25 08:00AM	IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications (GlobeNewswire)
Aug-07-25 04:00PM	IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +7.44%
Jun-09-25 07:00AM	IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial (GlobeNewswire) -26.14%
Jun-02-25 07:30AM	IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival (GlobeNewswire) -9.78%
May-14-25 08:00AM	IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 (GlobeNewswire) -8.31%
May-12-25 08:00AM	IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary ?d T cell Manufacturing Generates Consistent and Robust Clinical Products (GlobeNewswire)
08:00AM	Loading…
08:00AM	IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary T cell Manufacturing Generates Consistent and Robust Clinical Products (GlobeNewswire)
May-07-25 04:00PM	IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-25 08:00AM	IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences (GlobeNewswire)
Apr-28-25 08:00AM	IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 (GlobeNewswire) -5.97%
Mar-31-25 08:00AM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta ( ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 (GlobeNewswire) -15.35%
Mar-18-25 08:05AM	IN8bio to Participate at the 11th Annual Immuno-Oncology 360 Conference 2025 (GlobeNewswire)
Mar-13-25 04:05PM	IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -9.04%
Mar-03-25 09:28AM	IN8bio Announces Advanced Gamma-Delta (?d) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases (GlobeNewswire)
09:28AM	IN8bio Announces Advanced Gamma-Delta ( ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases (GlobeNewswire)
Feb-26-25 08:00AM	IN8bio to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-24-25 08:00AM	IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Feb-14-25 09:00AM	IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML (GlobeNewswire) -10.00%
Feb-11-25 08:00AM	IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients (GlobeNewswire) +13.59%
Jan-06-25 07:00AM	IN8bio to Present at Biotech Showcase 2025 in San Francisco (GlobeNewswire) +19.42%
Dec-10-24 07:00AM	IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting (GlobeNewswire) -9.25%
07:00AM	Loading…
Dec-02-24 07:00AM	IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference (GlobeNewswire) +20.77%
Nov-25-24 07:00AM	IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-12-24 04:26PM	IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.39% -9.49%
07:00AM	IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-05-24 09:00AM	IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +21.10%
Oct-01-24 08:00AM	IN8bio Announces Pricing of $12.4 Million Private Placement (GlobeNewswire)
Sep-05-24 08:33AM	IN8bio cuts staff and pipeline to focus on AML cell therapy (Pharmaceutical Technology) -27.33%
Sep-04-24 04:01PM	IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia (GlobeNewswire) -7.02%
Aug-29-24 06:05AM	IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 08:05AM	IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 (GlobeNewswire) -9.13%
Aug-08-24 04:05PM	IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-24-24 08:00AM	IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire)
Jun-14-24 02:04PM	IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking (Barrons.com) -35.12%
Jun-13-24 04:01PM	IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 (GlobeNewswire) +14.29%
Jun-03-24 06:05AM	IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.40%
May-24-24 08:00AM	IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 (GlobeNewswire)
May-23-24 05:00PM	IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress (GlobeNewswire)
May-13-24 08:00AM	IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 (GlobeNewswire)
May-09-24 10:57PM	INAB Stock Earnings: IN8bio Misses EPS for Q1 2024 (InvestorPlace)
04:00PM	IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-30-24 06:05AM	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire)
Apr-24-24 08:00AM	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 04:05PM	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-09-24 04:30PM	IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire)
Mar-14-24 09:54PM	INAB Stock Earnings: IN8bio Misses EPS for Q4 2023 (InvestorPlace) -7.20%
04:00PM	IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire) -7.26%
Feb-26-24 08:00AM	IN8bio to Present at Upcoming Investor Conferences (Business Wire)
Feb-14-24 08:00AM	IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology (GlobeNewswire) -6.67%
Jan-04-24 08:00AM	IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) +12.10%
Dec-11-23 04:05PM	IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia (GlobeNewswire) +29.29% +27.73%
09:00AM	IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement (GlobeNewswire)
Dec-07-23 08:00AM	IN8bio Appoints Dr. Corinne Epperly to Board of Directors (GlobeNewswire) -5.08%
Dec-05-23 08:00AM	IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia (GlobeNewswire)
Nov-20-23 07:00AM	IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma (GlobeNewswire)
Nov-10-23 07:00AM	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.61%
Nov-06-23 08:00AM	IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-02-23 09:17AM	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 08:00AM	IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-12-23 08:00AM	IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire) -5.00%
Sep-29-23 08:00AM	IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.31%
Sep-26-23 08:00AM	IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City (GlobeNewswire)
Sep-20-23 08:00AM	IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +12.62%
Sep-19-23 08:03AM	IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents (GlobeNewswire) +7.80%
Sep-06-23 08:00AM	IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 08:00AM	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-10-23 04:15PM	IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility (GlobeNewswire)
Jun-05-23 08:00AM	IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting (GlobeNewswire) -13.33%
May-17-23 08:00AM	IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer (GlobeNewswire)
May-12-23 08:00AM	IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.80%
May-02-23 05:08PM	IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting (GlobeNewswire) +21.84% +11.32%
May-01-23 08:00AM	IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors (GlobeNewswire) +19.18%
Apr-26-23 10:00AM	IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma (GlobeNewswire) -36.33%
Apr-24-23 08:00AM	IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 (GlobeNewswire) +185.71%
Apr-17-23 09:00AM	IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) +6.61%
Apr-11-23 08:00AM	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting (GlobeNewswire) +10.66%
Mar-30-23 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.11%
Mar-16-23 08:00AM	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) -7.52%
Mar-01-23 08:00AM	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) +5.88%
Feb-23-23 07:00AM	IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) -9.44%
Feb-21-23 07:00AM	IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-17-23 07:00AM	IN8bio to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (GlobeNewswire)
Jan-05-23 07:00AM	IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire)
Jan-03-23 07:00AM	IN8bio to Present at Biotech Showcase 2023 in San Francisco (GlobeNewswire)
Dec-12-22 07:00AM	IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 (GlobeNewswire)

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rochlin Kate	Chief Operating Officer	Apr 30 '25	Option Exercise	0.18	12,295	2,267	55,169	May 07 08:45 PM
McCall Patrick	CHIEF FINANCIAL OFFICER	Apr 30 '25	Option Exercise	0.18	15,000	2,766	67,071	May 07 08:45 PM
Roemer Alan S.	Director	Apr 30 '25	Option Exercise	0.18	113,459	20,922	398,489	May 07 08:45 PM
Brandt Peter C.	Director	Apr 30 '25	Option Exercise	0.18	163,934	30,229	681,538	May 07 08:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INAB

IN8bio Inc

Upgrade your Finviz experience